Premium
MiR‐146a‐5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor‐alpha inhibitor adalimumab
Author(s) -
Mensà E.,
Recchioni R.,
Marcheselli F.,
Giuliodori K.,
Consales V.,
Molinelli E.,
Prattichizzo F.,
Rippo M. R.,
Campanati A.,
Procopio A.D.,
Olivieri F.,
Offidani A.M.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16659
Subject(s) - adalimumab , psoriasis , medicine , tumor necrosis factor alpha , necrosis , alpha (finance) , dermatology , oncology , pathology , immunology , surgery , construct validity , patient satisfaction
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom